Functional Study of Leishmania braziliensis Protein Arginine Methyltransferases (PRMTs) Reveals That PRMT1 and PRMT5 Are Required for Macrophage Infection

被引:11
|
作者
Lorenzon, Lucas [1 ]
Quilles Jr, Jose C. [1 ]
Campagnaro, Gustavo Daniel [1 ]
Orsine, Lissur Azevedo [1 ]
Almeida, Leticia [1 ]
Veras, Flavio [2 ]
Miserani Magalhaes, Rubens Daniel [1 ]
Diniz, Juliana Alcoforado [1 ]
Ferreira, Tiago Rodrigues [3 ]
Cruz, Angela Kaysel [1 ]
机构
[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Cell & Mol Biol, BR-14096089 Sao Paulo, Brazil
[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pharmacol, BR-14096089 Sao Paulo, Brazil
[3] NIAID, Lab Parasit Dis, NIH, Bethesda, MD 20892 USA
来源
ACS INFECTIOUS DISEASES | 2022年 / 8卷 / 03期
基金
巴西圣保罗研究基金会; 美国国家卫生研究院;
关键词
Leishmania braziliensis; protein arginine methyltransferase; RNA-binding protein; arginine methylation; posttranslational modification; CRISPR/Cas9; STABLE TRANSFECTION; METHYLATION; ENZYME;
D O I
10.1021/acsinfecdis.1c00509
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In trypanosomatids, regulation of gene expression occurs mainly at the posttranscriptional level, and RNA-binding proteins (RBPs) are key players in determining the fates of transcripts. RBPs are targets of protein arginine methyltransferases (PRMTs), which posttranslationally regulate the RNA-binding capacity and other RBP interactions by transferring methyl groups to arginine residues (R-methylation). Herein, we functionally characterized the five predicted PRMTs in Leishmania braziliensis by gene knockout and endogenous protein HA tagging using CRISPR/Cas9 gene editing. We report that R-methylation profiles vary among Leishmania species and across L. braziliensis lifecycle stages, with the peak PRMT expression occurring in promastigotes. A list of PRMT-interacting proteins was obtained in a single coimmunoprecipitation assay using HA-tagged PRMTs, suggesting a network of putative targets of PRMTs and cooperation between the R-methylation writers. Knockout of each L. braziliensis PRMT led to significant changes in global arginine methylation patterns without affecting cell viability. Deletion of either PRMT1 or PRMT3 disrupted most type I PRMT activity, resulting in a global increase in monomethyl arginine levels. Finally, we demonstrate that L. braziliensis PRMT1 and PRMT5 are required for efficient macrophage infection in vitro, and for axenic amastigote proliferation. The results indicate that R-methylation is modulated across lifecycle stages in L. braziliensis and show possible functional overlap and cooperation among the different PRMTs in targeting proteins. Overall, our data suggest important regulatory roles of these proteins throughout the L. braziliensis life cycle, showing that arginine methylation is important for parasite-host cell interactions.
引用
收藏
页码:516 / 532
页数:17
相关论文
共 43 条
  • [31] A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with advanced solid tumors and lymphoma
    McKean, Meredith
    Patel, Manish R.
    Wesolowski, Robert
    Ferrarotto, Renata
    Stein, Eytan M.
    Shoushtari, Alexander N.
    Mauro, David
    Viscusi, John
    Scherle, Peggy
    Bhagwat, Neha
    Sun, William
    Chiaverelli, Rachel
    Mintah, Eric
    Jauhari, Shekeab
    Finn, Laura
    Palmisiano, Neil D.
    Baiocchi, Robert A.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [32] METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors
    Postel-Vinay, S.
    Italiano, A.
    Romano, P. Martin
    Cassier, P. A.
    Siu, L. L.
    Lossos, I. S.
    Hilton, J. F.
    Mckean, M. A.
    Strauss, J.
    Falchook, G. S.
    de Jonge, M. J. A.
    Opdam, F. L.
    Rasco, D.
    Vermaat, J. S.
    Crossman, T.
    Zajac, M.
    Hainline, A.
    Kremer, B.
    Barbash, O.
    Gounder, M. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S746 - S747
  • [33] METEOR-1: A phase I study GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours
    Siu, L. L.
    Rasco, D. W.
    Vinay, S. Postel
    Romano, P. Martin
    Menis, J.
    Opdam, F. L.
    Heinhuis, K. M.
    Egger, J. L.
    Gorman, S. A.
    Parasrampuria, R.
    Wang, K.
    Kremer, B. E.
    Gounder, M. M.
    ANNALS OF ONCOLOGY, 2019, 30 : 159 - 159
  • [34] A phase I study of safety, pharmacokinetics, and pharmacodynamics of SCR-6920, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced malignant tumors
    Yu, J.
    Sun, Y.
    Guo, S.
    Wang, H. Q.
    Wu, J.
    Jiang, X.
    Chen, J.
    Yang, G.
    Yang, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S474 - S474
  • [35] Activation of PRMT1 and PRMT5 mediates hypoxia- and ischemia-induced apoptosis in human lung epithelial cells and the lung of miniature pigs: The role of p38 and JNK mitogen-activated protein kinases
    Lim, Seul Ki
    Jeong, Yong Wun
    Kim, Dong Il
    Park, Min Jung
    Choi, Joo Hee
    Kim, Se Un
    Kang, Seong Soo
    Han, Ho Jae
    Park, Soo Hyun
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 440 (04) : 707 - 713
  • [36] Protein arginine methyltransferase 5 (PRMT5) activates WNT/β-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3
    Shailesh, Harshita
    Siveen, Kodappully S.
    Sif, Said
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (03) : 1583 - 1600
  • [37] Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies
    Bewersdorf, Jan Philipp
    Mi, Xiaoli
    Lu, Bin
    Kuykendall, Andrew
    Sallman, David
    Patel, Manish
    Stevens, Don
    Philipovskiy, Alexander
    Sutamtewagul, Grerk
    Masarova, Lucia
    Keiffer, Gina
    Verma, Amit
    Bhagwat, Neha
    Wang, Min
    Moore, Andrew
    Rager, Joseph
    Heiser, Diane
    Ro, Sunhee
    Hong, Wan-Jen
    Abdel-Wahab, Omar
    Stein, Eytan M.
    LEUKEMIA, 2025, 39 (03) : 765 - 769
  • [38] Discovery and structure-activity analysis of 4-((5-nitropyrimidin-4-yl)amino)benzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitors
    Yu, Xu-Ri
    Tang, Yun
    Wang, Wen-Jing
    Ji, Sen
    Ma, Shuang
    Zhong, Lei
    Zhang, Chun-Hui
    Yang, Jiao
    Wu, Xiao-Ai
    Fu, Zheng-Yan
    Li, Lin-Li
    Yang, Sheng-Yong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (22) : 5449 - 5453
  • [39] Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies
    Bewersdorf, Jan Philipp
    Mi, Xiaoli
    Lu, Bin
    Kuykendall, Andrew T.
    Sallman, David
    Patel, Manish
    Stevens, Don A.
    Philipovskiy, Alexander
    Sutamtewagul, Grerk
    Masarova, Lucia
    Keiffer, Gina
    Uerma, Amit
    Bhagwat, Neha
    Heiser, Diane
    Ro, Sunhee
    Hong, Wan-Jen
    Abdel-Wahab, Omar
    Stein, Eytan M.
    BLOOD, 2024, 144 : 3217 - 3217
  • [40] A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM)
    Monga, Varun
    Johanns, Tanner Michael
    Stupp, Roger
    Chandra, Sunandana
    Falchook, Gerald Steven
    Giglio, Pierre
    Philipovskiy, Alexander
    Alnahhas, Iyad
    Babbar, Naveen
    Sun, William
    McKean, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)